Superselective Renal Artery Embolization for Renal Angiomyolipoma Observational Study NCT07538908
Summary
NIH ClinicalTrials.gov has registered a new observational study (NCT07538908) evaluating superselective renal artery embolization as a treatment for renal angiomyolipoma. The prospective study will assess changes in serum creatinine and hemoglobin levels post-procedure, technical success rates, and complication incidence. Enrollment criteria include radiologically confirmed angiomyolipoma based on CT/MRI findings with clinical indications for embolization.
What changed
NIH has registered a new prospective observational study (NCT07538908) titled 'Superselective Renal Artery Embolization for Renal Angiomyolipoma' on ClinicalTrials.gov. The study will evaluate the efficacy and safety of selective endovascular embolization in treating renal angiomyolipoma through assessment of serum creatinine and hemoglobin level changes, technical success rates, and complications. Inclusion criteria require radiologically confirmed angiomyolipoma via CT and/or MRI with clinical indications for embolization.
Healthcare providers participating in or referring patients for renal angiomyolipoma treatment may wish to be aware of this study as it may inform future treatment protocols. The study's focus on preserving renal function while achieving technical success represents a key endpoint of interest for clinical decision-making in this patient population.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Superselective Renal Artery Embolization for Renal Angiomyolipoma
Observational NCT07538908 Kind: OBSERVATIONAL Apr 20, 2026
Abstract
To evaluate the efficacy and safety of selective endovascular embolization in the treatment of renal angiomyolipoma (AML). Materials and Methods: A prospective analysis will be conducted on patients who undergo transcatheter renal artery embolization for renal angiomyolipoma. Inclusion criteria will be radiologically confirmed angiomyolipoma based on CT and/or MRI findings and the presence of clinical indications for embolization. The primary outcomes will include the assessment of changes in serum creatinine and hemoglobin levels post-procedure, technical success rates, and the incidence of any complications. Expected Results: Data on patient demographics, tumor characteristics, and procedural outcomes will be collected and analyzed. Conclusion: This study aims to determine whether selective endovascular embolization is a safe and effective treatment modality for renal angiomyolipoma, with the expectation of demonstrating a high rate of technical success while preserving renal function.
Conditions: Selective Endovascular Embolization of Kidney Artery
Interventions: Selective endovascular embolization of kidney artery
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.